HOLOGIC (HOLX) Company Report

Hologic’s Aptima® HPV Assay received FDA approval for clinician-collected primary HPV screening, expanding options for cervical cancer prevention.
The test is the only FDA-approved mRNA-based HPV assay, designed to detect infections most likely to lead to cervical cancer.
With this approval, Hologic’s cervical health portfolio now includes three guideline-recommended screening methods: Pap + HPV co-testing, Pap testing, and HPV primary screening.
This additional indication follows clearance of the Genius® Digital Diagnostics System with the Genius® Cervical AI Algorithm.

9 hours ago

Press Release

Hologic announces Q1 FY2026 results

HOLX

Earnings

M&A

Hologic reported revenue of $1,047.8 million, up 2.5% year-over-year for Q1 FY2026.
GAAP diluted EPS was $0.79, a 9.2% decline, while non-GAAP diluted EPS rose 1.0% to $1.04.
Diagnostics revenue totaled $464.4 million (-1.3%) and Breast Health revenue was $375.9 million (+1.8%).
The company scheduled a special stockholders meeting on February 5, 2026 to vote on the merger with Blackstone and TPG.
Cash and cash equivalents at quarter end were $2.17 billion, with an adjusted net leverage ratio of 0.3×.

6 days ago

8-K

Hologic announces Q1 FY2026 results

HOLX

Earnings

M&A

Hologic scheduled a special meeting of stockholders on February 5, 2026 to vote on adopting the merger agreement with funds managed by Blackstone and TPG.
Revenue was $1,047.8 million, up 2.5% year-over-year; GAAP diluted EPS was $0.79, down 9.2%, and non-GAAP diluted EPS was $1.04, up 1.0%.
Diagnostics revenue declined to $464.4 million (−1.3%), Breast Health rose to $375.9 million (+1.8%), and Surgical reached $180.8 million (+8.7%).
Operating cash flow increased 21.4% to $229.9 million; the company ended the quarter with $2.17 billion in cash and an adjusted net leverage ratio of 0.3×.

6 days ago

Press Release

Hologic supplements proxy statement, discloses recall and settlement

HOLX

M&A

Legal Proceedings

Profit Warning

Hologic is supplementing its definitive proxy statement to address class action lawsuits and demand letters alleging omissions in its merger-related disclosures under the pending Blackstone/TPG acquisition.
Goldman Sachs’ illustrative DCF analysis, using discount rates of 8.5%–10.5% and perpetuity growth of 2.0%–3.0%, implies a per-share valuation range of $66.67–$99.09.
The voluntary recall and extended stop-ship of Brevera 9 Gauge Needles, which accounted for ~4.7% of fiscal 2025 Breast Health revenue, may pressure fiscal 2026 results and reduce the CVR net present value below $2.54 per right.
Hologic reached a product-liability settlement for BioZorb marker claims, fully covered by insurance, resulting in no expected Company liability.

Jan 26, 2026, 9:30 PM

8-K

Hologic faces investigation into proposed sale to Blackstone and TPG

HOLX

M&A

Legal Proceedings

Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti are investigating whether the proposed sale of Hologic, Inc. to funds managed by Blackstone and TPG provides adequate consideration and followed a fair process.
Under the deal, Hologic shareholders would receive $76.00 per share in cash plus a non-tradable contingent value right of up to $3.00 per share paid in two installments of up to $1.50 each.
KSF is soliciting shareholders who believe the transaction undervalues the company to discuss their legal rights at no cost or obligation.

Jan 7, 2026, 10:13 PM

Press Release

Hologic shareholders urged to contact law firm over sale

HOLX

M&A

Legal Proceedings

Takeover Bid

Halper Sadeh LLC is investigating Hologic, Inc.’s sale to funds managed by Blackstone and TPG for potential securities-law violations and fiduciary breaches.
Under the proposed transaction, shareholders will receive $76.00 per share in cash plus a non-tradable contingent value right of up to $3.00 per share in two payments of $1.50 each.
Shareholders are urged to contact Halper Sadeh LLC promptly to discuss enforcement of their rights; the firm will handle matters on a contingent fee basis.
The firm may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders.

Dec 23, 2025, 11:56 PM

Press Release

Hologic under class action scrutiny over sale to Blackstone and TPG

HOLX

Legal Proceedings

M&A

Monteverde & Associates PC is investigating Hologic’s $13.4 billion sale to funds managed by Blackstone and TPG, under which shareholders will receive $76.00 per share in cash plus a contingent value right of up to $3.00 per share in two $1.50 payments.
The alert is offered at no cost or obligation, backed by a Top 50 securities class action firm based in New York City.
The firm is simultaneously probing related M&A deals for MidWestOne (0.3175 share exchange ratio), Nicolet Bankshares, and American Water’s merger with Essential Utilities (resulting in ~69% ownership).

Nov 21, 2025, 10:30 PM

Press Release

Hologic expands CE marking for Genius™ Digital Diagnostics

HOLX

Product Launch

Hologic’s Genius™ Digital Diagnostics System achieved expanded CE marking in the EU to image and review both cell and tissue specimens using whole slide imaging.
The upgrade allows European labs to unify their digital pathology workflows on a single platform, aiming to reduce operational costs and turnaround times.
The expansion includes new software features—remote support, LIS readiness and advanced review tools—to enhance diagnostic efficiency.
Whole slide imaging remains unavailable in the United States; commercialization details will be announced by country.

Nov 12, 2025, 1:11 PM

Press Release

Hologic announces Q4 2025 results

HOLX

Earnings

M&A

Guidance Update

Hologic reported Q4 revenue of $1,049.5 million, up 6.2% year-over-year; GAAP diluted EPS of $0.83, up 9.2%, and non-GAAP diluted EPS of $1.13, up 11.9%.
On October 21, 2025, Hologic agreed to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share.
By segment, Diagnostics revenue was $454.1 million (+2.4%), Breast Health revenue was $393.7 million (+4.8%), and Surgical revenue was $172.5 million (+10.2%).
Operating cash flow was $355.1 million in the quarter and cash and cash equivalents ended at $1.96 billion; the company has withdrawn its FY2026 guidance due to the pending acquisition.

Nov 3, 2025, 9:01 PM

8-K

Hologic reports Q4 2025 results

HOLX

Earnings

M&A

Hologic recorded $1.0495 B in Q4 2025 revenue, up 6.2% year-over-year, and delivered $1.13 non-GAAP diluted EPS, up 11.9%.
Non-GAAP operating margin expanded 120 bps to 31.2% in Q4 2025.
Organic revenue excluding COVID-19 assays reached $998.6 M, growing 6.2% on a constant-currency basis.
The company announced it will be acquired by Blackstone and TPG for $76 per share in cash plus a contingent value right of up to $3, with closing expected in H1 2026.
Hologic ended Q4 2025 with $2.2 B in cash and investments and a net leverage ratio of 0.4×, providing strategic flexibility.

Nov 3, 2025, 9:00 PM

Presentation

Earnings Transcripts

Quarterly earnings call transcripts for HOLOGIC.

Q3 2025

Jul 30, 2025

→

Q2 2025

May 1, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Stephen P. MacMillan say about margins?What are HOLOGIC's strategic priorities?How is HOLOGIC positioned vs competitors?How did HOLOGIC do last quarter?

HOLOGIC (HOLX)

Analyst Earnings Quarterly Reports

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q1 2026

Executives

Stephen P. MacMillan

Anne M. Liddy

Brandon Schnittker

Diana De Walt

Essex D. Mitchell

Jan Verstreken

Jennifer M. Schneiders

Karleen M. Oberton

Mark Horvath

Board Members

Amy M. Wendell

Charles J. Dockendorff

Christiana Stamoulis

Ludwig N. Hantson

Martin Madaus

Nanaz Mohtashami

Stacey D. Stewart

Wayde McMillan

Analyst Coverage

Anthony Petrone

Casey Woodring

Jack Meehan

Patrick Donnelly

Andrew Cooper

Puneet Souda

Tejas Savant

Vijay Kumar

Andrew Brackmann

Conor Noel McNamara

Lu Li

Mason Carrico

Michael Ryskin

Avery Kriss

Dan Leonard

Douglas Schenkel

Doug Schenkel

Harrison Parsons

Jack Melick

Joseph Conway

Kevin Joaquin

Michael Matson

Navann Ty

Navann Ty Dietschi

Ryan Zimmerman

Tycho Peterson

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Ask Fintool AI Agent